Immuno-Oncology

The European Commission has approved nivolumab (Opdivo) for use in previously treated patients with advanced renal cell carcinoma.

The European Commission has approved nivolumab (Opdivo) for the treatment of patients with nonsquamous non–small cell lung cancer, regardless of PD-L1 levels.

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the adjuvant use of ipilimumab (Yervoy) in patients with melanoma.

PD-1/PD-L1 should be the backbone of melanoma treatment for many patients, says Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine.

Edward Kim, MD, discusses the impact of nivolumab (Opdivo) and pembrolizumab (Keytruda) in non–small cell lung cancer, potential combinations, biomarkers, and ongoing research.

The future looks bright for immunotherapies and novel targeted approaches for patients with gliomas, many of which have already been developed for other types of cancer.

Immunotherapy should be considered along with VEGF and mTOR TKIs as a highly effective treatment modality for patients with metastatic renal cell carcinoma.

Tara C. Mitchell, MD, discusses what oncologists need to know about using immunotherapies in melanomaâ€â€

Sarah Goldberg, MD, MPH, discusses the efficacy of immunotherapies, PD-L1 as a biomarker, and how these therapies will continue to alter the treatment of patients with non–small cell lung cancer.

The combination of ipilimumab and nivolumab has received a positive recommendation from the CHMP, which suggests that the treatment is likely to gain European approval for patients with advanced melanoma.

Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

The European Medicines Agency validated an application for use of nivolumab (Opdivo) for previously treated patients with classical Hodgkin lymphoma), which officially begins the centralized review process for final approval of the drug in the European Union.

After nearly 30 years of research, tumor-infiltrating lymphocyte technology is being investigated as a means of producing personalized immunotherapy for patients with metastatic melanoma in a small clinical trial that may help open the door for broader application in other solid tumor types.

H. Thomas Temple, MD, explains where he sees the future of sarcoma going and what diagnostic technologies and therapeutic advancements he is most excited about.

Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.

Tanguy Seiwert, MD, discusses the impact of the CheckMate-141 trial in head and neck cancer, the importance of establishing an effective biomarker, and the significance a manageable toxicity profile may have on patients with poor performance status.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses immunotherapy agents for the treatment of patients with bladder cancer.

Mario Sznol, MD, discusses the current state of immunotherapy in renal cell carcinoma, emerging agents and combinations in the field, and the challenges that arise with finding biomarkers.